CURE’s colorectal cancer page is an extensive resource of cancer information featuring the latest colorectal cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on colorectal cancer.
March 28th 2025
Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% disease control rate.